Related Experiment Videos

Toxicological studies on bestatin. I. Acute toxicity test in mice, rats and dogs

Insights

Bestatin (NK421) demonstrated very low acute toxicity via oral administration in mice, rats, and dogs. However, subcutaneous and intraperitoneal injections revealed target organ toxicity in kidneys, lymphoid tissues, and liver.

Area of Science:

  • Pharmacology
  • Toxicology

Background:

  • Bestatin is an aminopeptidase inhibitor with potential therapeutic applications.
  • Understanding the acute toxicity profile of bestatin (NK421) is crucial for its safe development.

Purpose of the Study:

  • To evaluate the acute toxicity of bestatin (NK421) in preclinical models.
  • To determine lethal dose 50 (LD50) values and identify potential target organs.

Main Methods:

  • Acute toxicity studies were conducted in male and female mice and rats, and male dogs.
  • NK421 was administered via oral, subcutaneous, and intraperitoneal routes.
  • Animals were observed for 14 days post-administration, with LD50 calculated using the probit method. Histopathological examinations were performed on dead animals.

Main Results:

  • Oral administration showed very low toxicity, with no deaths at maximum doses (4 g/kg in mice, 2 g/kg in rats, 1.2 g/kg in dogs).
  • Subcutaneous and intraperitoneal injections in rodents resulted in toxic signs including depression, suppressed movement, anorexia, and emaciation, with deaths occurring within 5 days.
  • Histopathology identified kidney, lymphoid tissue, and liver as primary target organs for toxicity.

Conclusions:

  • Bestatin (NK421) exhibits a favorable safety profile when administered orally.
  • Non-oral routes of administration present potential toxicity concerns, targeting the kidney, lymphoid tissue, and liver.

Related Concept Videos